CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
56.50
-0.83 (-1.45%)
At close: Mar 6, 2026, 4:00 PM EST
56.42
-0.08 (-0.14%)
After-hours: Mar 6, 2026, 7:59 PM EST
CRISPR Therapeutics AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 | |
| Revenue Growth (YoY) | -90.59% | -89.95% | 30885.48% | -99.87% | 127154.94% | |
| Cost of Revenue | 498.29 | 430.9 | 517.58 | 571.9 | 441.75 | |
| Gross Profit | -494.78 | -393.59 | -146.38 | -570.7 | 473.22 | |
| Selling, General & Admin | 73.54 | 72.98 | 76.16 | 102.46 | 99.69 | |
| Operating Expenses | 73.54 | 72.98 | 76.16 | 102.46 | 99.69 | |
| Operating Income | -568.32 | -466.57 | -222.54 | -673.16 | 373.53 | |
| Interest & Investment Income | - | - | - | 22.66 | 6 | |
| Other Non Operating Income (Expenses) | 86.61 | 103.9 | 71.82 | - | - | |
| EBT Excluding Unusual Items | -481.71 | -362.67 | -150.72 | -650.5 | 379.53 | |
| Pretax Income | -577.97 | -362.67 | -150.72 | -650.5 | 379.53 | |
| Income Tax Expense | 3.63 | 3.59 | 2.89 | -0.33 | 1.87 | |
| Earnings From Continuing Operations | -581.6 | -366.25 | -153.61 | -650.18 | 377.66 | |
| Net Income | -581.6 | -366.25 | -153.61 | -650.18 | 377.66 | |
| Net Income to Common | -581.6 | -366.25 | -153.61 | -650.18 | 377.66 | |
| Shares Outstanding (Basic) | 90 | 84 | 79 | 78 | 76 | |
| Shares Outstanding (Diluted) | 90 | 84 | 79 | 78 | 80 | |
| Shares Change (YoY) | 6.60% | 6.49% | 1.90% | -3.29% | 21.90% | |
| EPS (Basic) | -6.47 | -4.34 | -1.94 | -8.36 | 4.97 | |
| EPS (Diluted) | -6.47 | -4.34 | -1.94 | -8.36 | 4.70 | |
| Free Cash Flow | -345.93 | -144.68 | -269.85 | -532.93 | 457.27 | |
| Free Cash Flow Per Share | -3.85 | -1.72 | -3.41 | -6.86 | 5.69 | |
| Gross Margin | - | - | -39.43% | - | 51.72% | |
| Operating Margin | -16191.40% | -1250.38% | -59.95% | -56190.40% | 40.82% | |
| Profit Margin | -16569.77% | -981.54% | -41.38% | -54271.70% | 41.28% | |
| Free Cash Flow Margin | -9855.50% | -387.72% | -72.69% | -44484.89% | 49.98% | |
| EBITDA | -548.84 | -447.31 | -202.7 | -648.99 | 391.48 | |
| EBITDA Margin | - | - | -54.61% | - | 42.79% | |
| D&A For EBITDA | 19.48 | 19.26 | 19.84 | 24.17 | 17.95 | |
| EBIT | -568.32 | -466.57 | -222.54 | -673.16 | 373.53 | |
| EBIT Margin | - | - | -59.95% | - | 40.82% | |
| Effective Tax Rate | - | - | - | - | 0.49% | |
| Revenue as Reported | 3.51 | 37.31 | 371.21 | 1.2 | 914.96 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.